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Abstract 34 
Objective 35 
The aim of this study was to describe the trajectory of physical symptoms, coping styles and 36 
quality of life (QoL) and the relationship between coping and QoL over the last year of life in 37 
women with recurrent ovarian cancer. 38 
Methods 39 
The patient cohort were women recruited to the Australian Ovarian Cancer Study who 40 
subsequently experienced recurrent, invasive ovarian cancer and completed at least one 41 
psychosocial assessment (optimism, minimisation, hopelessness/helplessness, QoL) during 42 
the last year of life (n=217).  43 
Results 44 
QoL declined sharply from six months before death. Lack of energy was the most prevalent 45 
symptom over three measurement periods (67-92%) and also the most severe. Anorexia 46 
(36-55%), abdominal swelling (33-58%), nausea (26-47%) and pain (26-43%) all increased 47 
in prevalence and severity towards the end of life. Higher optimism (p=0.009), higher 48 
minimisation (p=0.003) and lower helplessness/hopelessness (p=0.03) at baseline were 49 
significant predictors of subsequent higher QoL. 50 
Conclusions 51 
Progressive deterioration in quality of life may be an indicator of death within about six 52 
months and therefore should be an important consideration in decisions about subsequent 53 
treatment. Coping styles which independently predicted subsequent changes in QoL could 54 
potentially be targeted by interventions to minimise worsening QoL.  55 
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Introduction 59 
Despite improvements in surgery, chemotherapy and targeted therapy, women with 60 
advanced ovarian cancer face a poor prognosis, with more than 50% dying within five years 61 
of diagnosis [1]. Patients and their families have to bear the increase in disease burden at 62 
the terminal stage of ovarian cancer, reflected in increasing physical symptoms and 63 
hospitalisations for complications such as ascites, bowel obstruction, pain and pleural 64 
effusion [2-3]. One of the most challenging clinical goals in caring for women with recurrent 65 
ovarian cancer is achieving the delicate balance between managing distressing cancer-66 
related symptoms and optimising quality of life (QoL) and knowing when to cease 67 
chemotherapy. Although it is well known that increased symptom severity has a negative 68 
impact on QoL in patients with cancer [4-5], including ovarian cancer [6], there is a paucity of 69 
data about symptoms and QoL in patients with recurrent ovarian cancer, especially in the 70 
terminal phase of the disease. 71 
The psychological and social impacts of recurrent and progressive disease, and how they 72 
inter-relate, also need to be better understood to guide optimal end of life care. There is 73 
increasing evidence that psychological morbidity at the end of life can be influenced by 74 
individual coping styles such as acceptance, avoidance and help seeking [7]. An active or 75 
accepting coping style, rather than an avoiding copying style, has been associated with 76 
better QoL [7-8], while there is some evidence that optimism and minimisation are 77 
associated with improved QoL [9] and longer survival [9-10]. Recent evidence suggests that 78 
social support, in particular social attachment, is associated with longer survival [11].  79 
Few studies have explored changes in, and the relationship between, symptoms of disease, 80 
coping styles and QoL in patients with terminal disease, and none in women with recurrent 81 
ovarian cancer. Therefore, the aims of the current study were to:  82 
(a) describe the most common and severe physical symptoms reported by women with 83 
recurrent ovarian cancer in the last year of life;  84 
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(b) describe the trajectory of coping styles and QoL in these women; and  85 
(c) evaluate the predictive relationship between coping styles one year prior to death and the 86 
subsequent trajectory of QoL in the final months of life. 87 
 88 
Methods 89 
Sample 90 
The Australian Ovarian Cancer Study (AOCS) is a prospective population-based study that 91 
recruited women aged 18-79 years newly diagnosed with primary epithelial ovarian cancer 92 
(including fallopian tube and primary peritoneal cancers) between 2002 and 2006. Details of 93 
the study have been described elsewhere [12]. In brief, women were recruited through major 94 
treatment centres and the state-based cancer-registries. The AOCS has collected detailed 95 
epidemiological data, pathology and initial treatment data, as well as ongoing treatment and 96 
clinical outcome data [12].  97 
The AOCS Quality of Life (AOCS-QoL) study has investigated the role of psychosocial 98 
factors in predicting outcomes, recruiting AOCS participants with invasive cancer who were 99 
alive in May 2005 or recruited to AOCS after this date [13]. Initial contact was made by 100 
AOCS to preserve confidentiality. Consenting women were mailed an information statement, 101 
consent form, questionnaire booklet and a reply paid envelope. Quality of Life and 102 
psychosocial data were collected by validated questionnaire measures at three-monthly 103 
intervals for up to two years, beginning 3-55 months post-diagnosis (mean 25.8 months) [13-104 
14]. If more than one item on any questionnaire was missing, the participant was contacted 105 
to complete the items; missing psychosocial data are therefore minimal. 106 
The current analyses include women in the AOCS-QoL study who completed at least one 107 
questionnaire assessment within their last year of life and who died before 1 May 2012. The 108 
study was approved and conducted in accordance with the ethical standards of the 109 
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University of Sydney, Queensland Institute of Medical Research Human Research Ethics 110 
Committees and all participating sites across Australia.  111 
Measures 112 
Primary outcome 113 
Quality of Life was assessed using the Functional Assessment of Cancer Therapy-Ovarian 114 
scale (FACT-O-version 4) [15] every three months. The FACT-O is a multi-dimensional, 115 
ovarian cancer-specific, quality of life instrument, assessing the four core QoL domains that 116 
together comprise the FACT-G: physical wellbeing (7 items); social wellbeing (7 items); 117 
emotional wellbeing (6 items); and functional wellbeing (7 items); together with 11 additional 118 
items assessing disease and treatment issues specific to ovarian cancer (symptom burden) 119 
(note: the item regarding interest in sex was excluded from analyses due to the high number 120 
of missing responses). Individual item responses range from 0 (not at all) to 4 (very much). 121 
FACT-O and domain scores are the sum of individual item responses. The physical, social, 122 
emotional and functional well-being domain scores range between 0-30, the symptom 123 
burden scores range between 0-50, and the overall FACT-O scores is standardised to range 124 
between 0-100. Higher scores reflect greater wellbeing. The minimally important difference 125 
(MID) for the FACT-G is six points on a standardised scale [16] and we expect this MID to be 126 
appropriate also for our standardised FACT-O scores. 127 
Descriptive and predictor variables 128 
Socio-demographics: Age, education, work and marital status were accessed via AOCS. 129 
Regional area (metropolitan/regional/remote) was calculated using the postcode of 130 
residential addresses. The Duke UNC Functional Social Support Questionnaire, measuring 131 
satisfaction with the functional and affective aspects of social support, was assessed every 132 
three months [17]. Scores range between 8-40 with higher scores indicating better social 133 
support. 134 
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Disease and treatment: Time between diagnosis and completion of the baseline 135 
questionnaire, surgical stage (I–IV, International Federation of Gynecology and Obstetrics 136 
(FIGO) classification) and date of death were accessed through AOCS. Current treatment 137 
information (chemotherapy, radiotherapy and/or hormonal treatment) was collected within 138 
each questionnaire, or from AOCS if missing. 139 
Coping variables: Optimism was assessed using the Life Orientation Test–Revised [18], a 140 
widely used 6-item measure of dispositional optimism. Scores range between 0-24 with a 141 
higher score indicating higher optimism. Two sub-scales of the Mental Adjustment to Cancer 142 
(MAC) scale [19] were used to measure helplessness/hopelessness and minimisation [20]. 143 
The six-item helplessness/hopelessness (HH) scores range between 6-24, with higher 144 
scores reflecting greater HH, and the 5-item minimisation scores range between 5-20, with 145 
higher scores reflecting greater minimisation. These three variables were measured every 146 
three months. 147 
Statistical analyses 148 
Months to death was calculated as the date of death minus the assessment date, rounded to 149 
the nearest month. The top five most severe symptoms from the FACT-O were identified for 150 
each of the three time periods (7-9, 4-6, and 0-3 months) separately. Prevalence for these 151 
symptoms was calculated as the percent who reported that symptoms bothered them “quite 152 
a bit” or “very much”. The following 16 variables were graphed over time (months to death), 153 
with 95% confidence intervals (CI): global QoL (FACT-O), physical wellbeing, social 154 
wellbeing, emotional wellbeing, functional wellbeing, symptom burden, optimism, 155 
minimisation, helplessness/hopelessness scores, and the seven individual symptom items 156 
identified within the top five symptom list. 157 
To assess trajectories over time, mixed models, which included months to death and its 158 
square as fixed effects, and a random participant effect, were fitted for each of the 16 159 
variables listed above. A statistically significant linear term for time indicates a steady 160 
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change in the outcome. A statistically significant linear and quadratic (non-linear) term for 161 
time indicates an increase or decrease as well as a change in the rate of increase or 162 
decrease over time. If neither linear nor quadratic (non-linear) terms are significant there is 163 
no evidence for change over time. 164 
The association between psychosocial coping variables (optimism, minimisation and 165 
helplessness/hopelessness) and global QoL (FACT-O) was investigated using mixed models 166 
among participants completing more than one assessment (n=158). Each participant’s 167 
earliest assessment observation in the year preceding death was used to predict all 168 
subsequent assessments of QoL. In addition to the coping variables, fixed effects of age, 169 
months to death, current social support and current treatment (yes/no: radiotherapy or 170 
chemotherapy); and a random effect of patient were included in the model. Current social 171 
support and treatment were included to control for potential influence on QoL at each time 172 
point. Mixed models account for the within participant correlation due to repeated measures 173 
and give unbiased estimation for data missing completely at random and missing at random 174 
[21]. All statistical analyses were performed in SAS version 9.3 (Cary, NC). 175 
 176 
Results 177 
Two hundred and seventeen AOCS-QoL study participants, with a total of 502 assessments 178 
completed during the last year of life, met the criteria for this analysis. Fifty-nine completed 179 
one (27%), 61 completed two (28%), 67 completed three (31%), and 30 completed four 180 
assessments (14%). Eighty-nine assessments were completed within the last three months 181 
of life, 130 between 4-6 months before death, 152 between 7-9 months before death and 182 
131 assessments between 10-12 months before death. 183 
Patient characteristics are presented in Table 1. The mean age of participants was 63 years, 184 
most were living as married (74%) and had advanced stage disease at diagnosis (93%, 185 
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FIGO III/IV). Fifty-three percent of patients who completed an assessment between 10-12 186 
months before death were receiving chemotherapy at the time, decreasing to 39% of 187 
patients who completed an assessment within the last three months of life. 188 
Physical symptoms and their trajectory in the last year of life 189 
The five most severe and common physical symptoms, from among individual FACT-O 190 
items, at three time frames within the last year of life (7-9 months, 4-6 months, 0-3 months 191 
before death), are displayed in Table 2. These included: lack of energy, poor appetite, 192 
stomach swelling, loss of bowel control, nausea, pain, and weight loss. All of these 193 
symptoms increased in prevalence and severity towards the end of life (see Figure 1). 194 
Prevalence was defined as the percentage of patients reporting a specific symptom as ‘quite 195 
a bit’ or ‘very much’. Severity was defined as the average score on the 0-4 scale, with higher 196 
scores reflecting greater severity. Lack of energy was both the most prevalent and most 197 
severe symptom reported in the last year of life, reported by 67% of women at 7-9 months 198 
before death, 78% at 4-6 months before death, increasing to 92% in the last three months of 199 
life. Loss of appetite was the second most severe symptom during the last year of life, while 200 
swollen abdomen was the second most prevalent symptom, present in 33% of patients at 7-201 
9 months before death increasing to 58% in the last three months of life. Losing weight 202 
appeared among the top five symptoms only within the last three months of life, overtaking 203 
pain which, although increasing in severity and prevalence, was not among the top five 204 
symptoms within the last three months of life (Figure 1). Exploratory analyses showed that 205 
currently receiving chemotherapy was significantly associated with increases in nausea 206 
(p<0.0001), vomiting (p=0.004) and lack of energy (p=0.06). 207 
Figure 2 displays the individual trajectories for FACT-O, physical wellbeing, social wellbeing, 208 
emotional wellbeing, functional wellbeing, symptom burden, optimism, minimisation and 209 
helplessness/hopelessness over the last year of life. Physical wellbeing and emotional 210 
wellbeing steadily decreased and helplessness/hopelessness steadily increased over time, 211 
reflected by significant p-values for the linear time terms. Not surprisingly, the physical 212 
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wellbeing decline was steepest, and can be attributed to three individual items (lack of 213 
energy, nausea and pain) not only being within the most prevalent and severe symptoms 214 
reported, but also steadily increasing as time to death decreased. 215 
Global QoL, functional wellbeing, symptom burden and minimisation scores also changed 216 
significantly over time, but the rates of change over time were variable rather than steady, as 217 
demonstrated by statistically significant non-linear (quadratic) time terms (Figure 2). Three of 218 
the most prevalent symptom items, all among the ovarian-specific symptom burden domain, 219 
also had a variable rate of change over time. Appetite decreased more steeply over the last 220 
six months of life, weight loss sharply increased in the last three months of life, and 221 
abdominal swelling sharply increased in the last two months of life.  222 
In contrast, there was no evidence of change over time in social wellbeing, optimism and 223 
minimisation scores, with both linear and non-linear (quadratic) terms non-significant. Of 224 
note, bowel control, which was among the top five most severe symptoms at 7-9 months 225 
before death, was approximately constant rather than increasing or decreasing over time.  226 
Coping and QoL trajectory in the last year of life  227 
The results of the linear mixed models analysis examining whether coping variables 228 
predicted subsequent quality of life are displayed in Table 3. Both older age (p=0.02) and 229 
better social support (p=0.002) were positively associated with subsequent QoL, while 230 
current treatment was not (p=0.2). Optimism (p=0.009), minimisation (p= 0.003) and 231 
helplessness/hopelessness (p=0.03) were all statistically significant predictors of subsequent 232 
QoL. A one-point increase in optimism was associated with an increase in QoL of 0.6 (95% 233 
CI: 0.2, 1.1); a one-point increase in minimisation was associated with an increase in QoL of 234 
1.1 (95% CI: 0.4, 1.8) and a one-point increase in helplessness/hopelessness was 235 
associated with a decrease in QoL of 0.8 (95% CI: -1.5, -0.1).  236 
 237 
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Discussion 238 
This large prospective study of women with recurrent ovarian cancer documents the 239 
changes in physical symptoms, coping styles and QoL over the last year of life and clearly 240 
demonstrates a substantial deterioration in symptoms and QoL in the six months before 241 
death. The findings raise important questions as well as illustrating the challenges in 242 
identifying these patients and how best to intervene to improve their end of life care. 243 
The most prevalent and most severe symptom was lack of energy, reported by 67% of 244 
patients 7-9 months before death and increasing to 92% in the last three months of life. 245 
Although fatigue is well recognised as a burdensome symptom in advanced cancer patients 246 
in general [4, 22] and ovarian cancer specifically [3], treatment options are limited. There is 247 
some evidence that a stimulant drug, methylphenidate may be effective [23], while physical 248 
exercise and psychosocial interventions have been shown to be effective in reducing fatigue 249 
in breast cancer survivors, and may be of benefit in patients in the terminal phase [24]. 250 
Anorexia, abdominal swelling and nausea were also prevalent and severe, worsening 251 
towards the end of life. Options to palliate these symptoms include drainage of ascites, 252 
percutaneous gastrosomies, stent placing, as well as symptomatic treatment of bowel 253 
obstruction with steroids and somatostatin [25]. There is evidence that bevacizumab and 254 
aflibercept targeting vascular endothelial growth factor, and catumaxomab, targeting EpCAM 255 
and anti-CD3, reduce ascites and could reduce the need for repetitive paracenteses [26-29]. 256 
Pain is a prevalent symptom at the end of life, highly prioritised by patients [30-31]. In our 257 
study, while other symptoms were more prevalent, pain remained an important symptom, 258 
with 46% of women reporting pain in the last three months of life (data not shown). While 259 
substantially less than the 85% of patients with ovarian cancer who had pain mentioned in 260 
their medical records during the last six months of life in the Rolnick et al. [32] study, given 261 
the substantial evidence available for the treatment and management of pain, the prevalence 262 
of patients reporting pain is unacceptably high [33-34]. 263 
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The QoL trajectory in the last year of life was variable, but invariably declined. In the first six 264 
months, the downward slope was gradual and took on average about four months to 265 
decrease by the minimal important difference of six. From about six months before death the 266 
QoL decline sharply steepened, mainly determined by declining physical and functional 267 
wellbeing and increasing single symptom severity. Although there are few data with which to 268 
compare our findings, a small study of 62 patients with recurrent ovarian cancer also showed 269 
that patients experienced increasing significant clinical events from six months before death 270 
[2].  271 
The progressive deterioration in quality of life evident in our data may be an indicator of 272 
death within about six months and therefore should be an important consideration in 273 
decisions about subsequent treatment. There is evidence from clinical trials that QoL is an 274 
independent prognostic factor for survival in patients with various types of cancer [35], 275 
including ovarian cancer [36]. A dip in patient QoL may be a useful clinical warning that the 276 
patient is entering the terminal phase of life, and may aid clinician and patient decision-277 
making regarding futile chemotherapy, thus reducing the number of patients who receive 278 
chemotherapy shortly before they die [2].  279 
Notably, we found no evidence that being on chemotherapy was associated with an 280 
additional improvement or deterioration in QoL. However, the observational nature of our 281 
study design does not enable us to determine whether chemotherapy was able to palliate 282 
symptoms, the main goal of treatment in patients with platinum-resistant, recurrent ovarian 283 
cancer. Research specifically designed to evaluate whether palliative chemotherapy 284 
improves symptoms in women with recurrent ovarian cancer is currently being conducted by 285 
the Australia New Zealand Gynaecological Oncology Group [37]. 286 
Parallel with an increase in physical disease burden, hopelessness/helplessness increased 287 
and minimisation decreased in the last year of life, as coping resources were increasingly 288 
strained. While it may not be surprising that cancer has an increasing impact at the end of 289 
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life, this may not only be a negative process. It may be necessary for patients and their 290 
families to move from hoping for a dramatic improvement to accepting and preparing for their 291 
approaching death [38]. More research into the nuances of hope and meaning at the end of 292 
life would enable greater understanding of the role of coping.  293 
A major finding of this study is that optimism, minimisation and hopelessness/ helplessness 294 
at the beginning of the last year of life were related to QoL as death approached. Vos et al. 295 
[39-40] found that some level of denial, although more extreme than minimisation, was 296 
associated with improved QoL in patients with lung cancer, independent of disease burden, 297 
suggesting a protective effect on social and emotional outcomes, while Van Laarhoven et al. 298 
[7] reported venting emotions was a negative predictor of emotional functioning at the end of 299 
life. These results do suggest that at least early in the last year of life, minimisation may help 300 
patients to retain a sense of joy and meaning in life independent of their cancer. Of clinical 301 
relevance, the potential benefit of interventions targeting specific aspects of coping, such as 302 
Mindfulness-based interventions or Acceptance/Commitment Therapy [41-43], in addition to 303 
symptoms such as anxiety, depression and insomnia, may offer some protection against the 304 
steepness of declining QoL in patients approaching the end of life. 305 
In conclusion, this study described the trajectory of physical symptoms, coping styles and 306 
QoL of women with recurrent ovarian cancer in their last year of life. Progressive 307 
deterioration in quality of life may be a reliable indicator of death within about six months and 308 
therefore should be an important consideration in decisions about subsequent treatment and 309 
help to identify patients who require supportive care rather than more chemotherapy. Coping 310 
styles independently predicted subsequent changes in QoL and provide additional 311 
psychosocial targets for intervention that have potential to impede some aspects of 312 
worsening QoL. Further research is required to elucidate the role of coping on QoL in the 313 
last year of life and whether early intervention can improve coping and QoL.  314 
(Word 2007 word count 3127)  315 
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Table 1. Descriptive statistics for patient demographics, disease stage at diagnosis, and 458 
treatment status at the first assessment during the last year of life.  459 
Variables (N=2171) Statistic 
 Mean (Standard Deviation) 
Age (in years) 62.6 (10.0) 
Months since diagnosis  25.8 (13.9) 
  
 N (%) 
Marital status  
     Current partner 153 (74) 
     Ex partner 43 (21) 
     Never married 12 (6) 
Education  
     School only (≤12 years) 100 (46) 
     Trade/Technical 66 (30) 
     University 47 (22) 
Residential location  
     Major city 134 (62) 
     Regional/remote 83 (38) 
FIGO stage at diagnosis  
     Early (I/II) 15 (7) 
     Advanced (III/IV) 199 (93) 
Current chemotherapy   
     Yes 102 (47) 
     No 115 (53) 
Current radiotherapy  
     Yes 2 (1) 
     No 215 (99) 
1Numbers may not add up to total due to missing data 460 
  461 
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Table 2. Prevalence of the five most severe symptoms from the FACT-O reported during 462 
each of three time periods (7-9 months before death, 4-6 months before death, and 0-3 463 
months before death).  464 
Months 
before 
death 
Symptom1 Mean severity 
(95% CI) 
Percent prevalence2 
(95% CI) 
7-9 months I have a lack of energy 2.2 (2.0, 2.4) 67 (59, 74) 
n = 152 I have a good appetite3 1.4 (1.1, 1.6) 36 (28, 43) 
 I have swelling in my 
stomach area 
1.3 (1.1,1.5) 33 (26, 41) 
 I have control of my bowels3 1.2 (1.0,1.4) 36 (28, 43) 
  I have nausea 1.0 (0.8, 1.2) 26 (19, 33) 
 I have pain 1.0 (0.8, 1.2) 26 (19, 34) 
    
4-6 months  I have a lack of energy 2.6 (2.4, 2.8) 78 (71, 86) 
n = 130  I have a good appetite3 1.9 (1.7, 2.1) 37 (29, 49) 
 I have swelling in my 
stomach area 
1.7 (1.4, 1.9) 46 (37, 55) 
 I have pain 1.4 (1.2. 1.7) 43 (34, 51) 
 I have nausea 1.3 (1.0. 1.5) 38 (30, 47) 
    
0-3 months I have a lack of energy 3.0 (2.8, 3.2) 92 (86, 98) 
n = 89 I have a good appetite3 2.5 (2.2, 2.8) 55 (45, 66) 
 I have swelling in my 
stomach area 
2.1 (1.7, 2.4) 58 (47, 68) 
 I am losing weight 1.8 (1.5, 2.1) 55 (45, 66) 
 I have nausea 1.5 (1.2, 1.8) 47 (37, 58) 
1 Symptom response options 0 = “not at all”, 1 = “a little bit”, 2 = “somewhat”, 3 = “quite a bit”, 465 
4 = “very much” 466 
2Prevalence is the percentage of women reporting 3 or 4.  467 
3 Item has been reverse coded so that higher scores reflect worsening appetite. 468 
 469 
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Table 3. Association of quality of life (FACT-O) with coping variables while controlling for 471 
months to death, age, social support, and current treatment. Regression coefficient 472 
estimates and 95% confidence intervals (CIs) from a mixed model are shown. Each 473 
participant’s first observation in the year preceding death for coping variables was used to 474 
predict all subsequent observations of QoL. 475 
Variable1 Estimate (95% 
CI) 
p-value 
Optimism 0.6 (0.2, 1.1) 0.009 
Minimisation 1.1 (0.4, 1.8) 0.003 
Helplessness/hopelessness -0.8 (-1.5, -0.1) 0.03 
Age 0.22 (0.04, 0.4) 0.02 
Months to death 2.6  (2.1, 3.1) <0.0001 
Current social support2 0.5 (0.2, 0.8) 0.002 
Current treatment2 -1.8 (-4.5, 0.9) 0.2 
1Optimism, minimisation, helplessness/hopelessness and age at the first assessment only 476 
were entered into the model; 2Current social support and treatment were entered as time-477 
varying covariates. 478 
 479 
 480 
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Figure legends 482 
 483 
Figure 1. Mean symptom scores over months to death, with 95% confidence intervals. 484 
Statistically significant p values for the linear and non-linear (quadratic) terms for time (from 485 
a mixed model) indicate an increase or decrease in the outcome, as well as a change in the 486 
rate of increase or decrease. If the linear term only is statistically significant there is evidence 487 
for a steady change. If neither linear nor non-linear (quadratic) terms are significant there is 488 
no evidence for change over time. 489 
 490 
Figure 2. Mean global QoL, physical, emotional, social, functional domains, symptom 491 
burden, optimism, minimisation, and helplessness/hopelessness, over months to death, with 492 
95% confidence intervals. Statistically significant p values for the linear and non-linear 493 
(quadratic) terms for time (from a mixed model) indicate an increase or decrease in the 494 
outcome, as well as a change in the rate of increase or decrease. If the linear term only is 495 
statistically significant there is evidence for a steady change. If neither linear nor non-linear 496 
(quadratic) terms are significant there is no evidence for change over time. 497 
 498 
